Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 11, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 650,000 Ordinary shares of 25 pence each.
- Purchase Date: April 11, 2007.
- Price per Share: 1,413.7258 pence.
- Treasury Holdings Post-Purchase: 284,692,678 shares.
- Shares in Issue (Excluding Treasury): 5,726,177,322 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 650,000 shares for Treasury. The filing does not provide comparative data against a prior period for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (284,692,678) against subsequent filings.
- Confirm the total voting rights denominator (5,726,177,322 shares) for disclosure threshold calculations under Financial Services Authority rules.
- Review the Annual General Meeting minutes from May 17, 2006, to confirm the scope of the share repurchase authority utilized.